Abstract:
Disclosed herein are optimized guide RNAs (gRNAs) and methods of designing and using said optimized gRNAs that have increased target binding specificity and reduced off-target binding.
Abstract:
The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a method of identifying an individual for eligibility for prostate cancer therapy. The invention also relates to products for the analysis of phosphodiesterase 4D (PDE4D) variants as well as pharmaceutical compositions modulating the activity and/or expression of PDE4D variants.
Abstract:
In some embodiments, systems and methods for storing and/or retrieving digital information in a nucleic acid library are provided. In some embodiments, an integrated system comprising a nucleic acid synthesis device, a nucleic acid sequencing device, a computing device, and a nucleic acid library is provided. In some embodiments, a write request that associates a value with a key is received by the system, the system synthesizes nucleic acid molecules associated with the request, and stores the nucleic acid molecules in the nucleic acid library. In some embodiments, a read request for a key is received by the system, and the system sequences nucleic acid molecules from the nucleic acid library that are associated with the key.
Abstract:
The present invention pertains to methods for determining the change in the immune repertoire of an individual suffering from disease or undergoing therapy for the treatment of a disease. The methods use the difference between the change in the level of immune cell diversity seen in an individual before, during or after a health event to determine the effect of the disease, or the effect of a treatment regime, on the individual. The difference in the level of immune cell diversity is referred to as the Delta Index and is defined as the quantitative and qualitative change (gain or loss of clones) of an individual's most dynamic immune cells over time.
Abstract:
Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.
Abstract:
Methods of evaluating or providing a clonal profile of a subject interval, e.g., a subgenomic interval, or an expressed subgenomic interval (or of a cell containing the same), in a subject, are disclosed.
Abstract:
Procédé d'estimation de l'affinité ϕ d'un premier brin d'ADN, ou « sonde », à s'hybrider avec un deuxième brin d'ADN, ou « cible », pour former un hybride de longueur L bp , le procédé comprenant; dans chaque division d'un ensemble de M divisions de l'hybride, compter le nombre de fois où chaque hybride d'un ensemble de P hybrides de brins d'ADN est présent dans la division, lesdits hybrides étant de longueur k inférieure à la longueur L bp , ou « k -hybrides »; pour chaque combinaison de défauts d'appariement d'un ensemble de L combinaisons de défauts d'appariement dans un hybride de longueur Lbp, déterminer si ledit couple de défauts d'appariement est présent dans ledit hybride; et calculer l'affinité ϕ selon la relation : ( ϕ) expression dans laquelle : - ∀( m, p ) ∈ [1, Μ ] x [1, P ], β p,m est un scalaire prédéterminé quantifiant la contribution à l'affinité ϕ du p ième k - hybride de l'ensemble de P k - hybrides lorsque ce p ième k -hybride est présent dans la m ième zone de ladite division, et x m,p est le nombre de fois où ce p ième k -hybride est dénombré pour ledit hybride dans la m ième zone de ladite division; et α est un terme réel.
Abstract:
Systems and methods are provided for determination of primers for differentiation of at least two unspecified pathogens that belong to distinct pathogen (e.g., virus) families that comprise multiple distinct pathogen species and/or varieties.
Abstract:
This invention relates to a method of classification of cancer type or subtype in a subject by detecting glycosyltransferase gene expression in a sample from the subject. In particular, where the method is for classification of cancer subtype in the subject the glycosyltransferase genes may be survival associated glycosyltransferase genes. The invention further relates to a kit comprising glycosyltransferase gene biomarkers for use with the method, and a method of treatment of cancer in a subject with the use of the method or kit of the invention.